Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

Samir S. Taneja

doi:10.1016/j.juro.2018.01.031

Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

Samir S. Taneja

Biomedical Engineering

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	893-894
Number of pages	2
Journal	The Journal of urology
Volume	199
Issue number	4
DOIs	https://doi.org/10.1016/j.juro.2018.01.031
State	Published - Apr 1 2018

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2018.01.031

Cite this

@article{38d623c110f84ed2a04ad40481158e05,

title = "Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA",

author = "Taneja, {Samir S.}",

year = "2018",

month = apr,

day = "1",

doi = "10.1016/j.juro.2018.01.031",

language = "English (US)",

volume = "199",

pages = "893--894",

journal = "The Journal of urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Re

T2 - Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

AU - Taneja, Samir S.

PY - 2018/4/1

Y1 - 2018/4/1

UR - http://www.scopus.com/inward/record.url?scp=85065675592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065675592&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2018.01.031

DO - 10.1016/j.juro.2018.01.031

M3 - Comment/debate

C2 - 29642359

AN - SCOPUS:85065675592

SN - 0022-5347

VL - 199

SP - 893

EP - 894

JO - The Journal of urology

JF - The Journal of urology

IS - 4

ER -

Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this